WEBULL
News
KYKOF
16.54
NaN%
--
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
TipRanks · 2d ago
Kyowa Kirin announces management changes
Seeking Alpha · 12/11 08:12
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML
Seeking Alpha · 12/08 18:00
Kura Oncology wins FDA approval for leukemia drug
Seeking Alpha · 11/13 15:28
Kyowa Kirin reports 9M results
Seeking Alpha · 10/30 16:14
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
TipRanks · 10/27 21:13
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
TipRanks · 10/27 21:00
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
TipRanks · 10/27 19:22
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
TipRanks · 10/27 18:26
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
TipRanks · 10/27 18:00
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
TipRanks · 10/27 17:59
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
TipRanks · 10/27 17:57
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
TipRanks · 10/27 17:18
Kyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
TipRanks · 10/27 17:16
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
TipRanks · 10/27 17:02
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
TipRanks · 10/01 11:15
Weekly Report: what happened at KYKOF last week (0908-0912)?
Weekly Report · 09/15 10:57
Jefferies Reaffirms Their Buy Rating on Kyowa Kirin Co (KYKOF)
TipRanks · 09/10 19:25
Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug
Seeking Alpha · 09/09 11:08
Weekly Report: what happened at KYKOF last week (0901-0905)?
Weekly Report · 09/08 10:59
More
Webull provides a variety of real-time KYKOF stock news. You can receive the latest news about Kyowa Hakko Kogy through multiple platforms. This information may help you make smarter investment decisions.
About KYKOF
Kyowa Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of medical drugs. The Company operates in Pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The Company operates in Japan and overseas.